Notably, blocking PD-1 and CTLA-4 ex vivo with monoclonal antibodies, and inhibiting PD-1 in vivo with pembrolizumab, has been shown to restore mutCALR-specific T-cell immunity in some mutCALR MPN patients. This evidence concerns the gene CTLA4 and myeloproliferative disorder.